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Available online 14 November 2017AbstractObjectives: This study aims to evaluate the feasibility of Breast Lesion Excision System (BLES) in the treatment of intraductal papillomas.
Material and methods: All patients with a needle biopsy ebased suspicion of an intraductal papilloma who consequently underwent a
BLES procedure at Helsinki University Hospital between 2011 and 2016 were included in this retrospective study. The purpose of the
BLES procedure was either to excise the entire lesion or in few cases to achieve better sampling.
Results: In total, 74 patients underwent 80 BLES procedures. Pathological diagnosis after the BLES biopsy confirmed an intraductal
papilloma without atypia in 43 lesions, whereas 10 lesions were upgraded to high-risk lesions (HRL) with either atypical ductal hyperplasia
or lobular carcinoma in situ. Five cases were upgraded to malignancy, two were invasive ductal carcinomas and three were ductal carcinoma
in situ. Additionally, 18 lesions were diagnosed as other benign lesions. Four procedures failed. Complete excision with BLES was achieved
in 19 out of 43 intraductal papillomas, 6 out of 10 HRL and two out of five malignant lesions. No major complications occurred. The BLES
procedure was adequate in the management of the 71 breast lesions.
Conclusion: The BLES procedure is an acceptable method for the management of small benign and high-risk breast lesions such as intra-
ductal papillomas in selected patients. Thus, a great amount of diagnostic surgical biopsies can be avoided.
 2017 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.
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Clinical, radiological and histological interpretation of
papillary lesions of the breast remains challenging due to
their wide morphological spectrum. Papillomas may be
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lsevier Ltd, BASO ~ The Association for Cancer Surgery,Peripheral papillomas are often multiple and central are
solitary. Papillomas may on the basis of the morphology
be classified into benign or papillomas associated with
atypical ductal hyperplasia (ADH) or papilloma associated
with ductal carcinoma in situ (DCIS) or malignant subtype
e.g. papillary carcinoma with adjacent invasive carcinoma.
Papillomas presenting as papillomatosis confers a higher
risk of malignancy [1,2].
It is not possible to exclude atypia nor malignancy by
core needle biopsy (CNB) or imaging [2e5]. Thus, the
standard of care in the management of papillomas is surgi-
cal excision. Intraductal papillomas without atypia could be
managed by follow-up and a surgical procedure could be
avoided [6]. However, follow-up can be stressful for theand the European Society of Surgical Oncology. All rights reserved.
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gested that a larger biopsy sample might decrease the risk
of sampling error [7e9].
The Breast Lesion Excision System (BLES; Intact;
Intact Medical Corporation, Framingham, USA) is a biopsy
device, which uses radiofrequency cautery to excise a sin-
gle spheroid tissue sample without fragmentation thus
making the histopathological analysis more accurate than
by CNB. In the USA, BLES was approved by the Food
and Drug Administration for sampling in 2001 and for
complete removal of lesions in 2005. The BLES technique
has shown to be a safe and potential alternative to tradi-
tional surgical excision for removal of small breast lesions
[10e14]. The underestimation rate seems to be lower with
the BLES than with vacuum-assisted core needle biopsy
(VACNB) [15,16]. Other benefits of the BLES in compari-
son to VACNB are the possibility to evaluate histological
margins and the ability of the BLES wire basket to perform
hemostasis. The BLES biopsy can be carried out as an
outpatient procedure.
The aim of this study is to evaluate the feasibility of
BLES in the treatment of intraductal papillomas in selected
patients.
Patients and methodsPatientsAll patients with a needle biopsy ebased suspicion of an
intraductal papilloma who consequently underwent a BLES
procedure at the Department of Radiology of Helsinki Uni-
versity Hospital (HUH) between November 2011 and June
2016 were included in this retrospective study. The patients
had a prior CNB or a fine needle aspiration cytology
(FNAC) sample taken. In one BI-RADS 4 lesion, neither
previous CNB nor FNAC was performed, but the lesion
was biopsied with the BLES at the same session with
another papilloma with a previous CNB. Only four of our
patients had had nipple discharge. The purpose of the
BLES was either to excise the entire lesion or in few cases
to get a greater amount of tissue for better sampling of the
lesion.
The patient data were collected into a database at the
time of the BLES procedure. The HUH Department of
Radiology is the first unit in Finland to use the BLES since
2011. The very first BLES procedures of our institute were
also included in this series. At the beginning, four of the pa-
tients with a high-risk lesion (HRL) and positive margins in
the BLES specimen were referred to surgical excision in or-
der to confirm the diagnosis and a complete removal. The
patients have been followed up since the first BLES proced-
ure until June 2016. The procedure data was collected from
the prospective database and additional data was gathered
from electronic patient records retrospectively. The institu-
tional research permission was granted by HUH Compre-
hensive Cancer Center.BLES procedureThe BLES device consists of a biopsy basket, which is
mounted into a wand. A wire basket emerges from the tip
of the wand cutting and cauterizing the breast tissue with
radiofrequency energy enveloping the target lesion. A sin-
gle intact spherical tissue sample may then be removed.
The basket sizes in our unit are 12 mm, 15 mm and
20 mm. The aim was always to use the largest basket
when possible (Fig. 1).
Contraindications for the BLES procedure were a car-
diac pacemaker, pregnancy and breastfeeding. Anticoagu-
lants such as clopidogrel and warfarin were recommended
to be stopped one week prior to the procedure.
The maximum size of the lesions was 10 mm in breast
ultrasound in order to achieve a complete excision. The
thickness of the breast, i.e. the distance between the pector-
alis muscle and the skin should be more than 14 mm so that
the wire basket could open safely and successfully. The
distance from the lesion to the skin and the pectoralis
muscle should be 3 mm and to the nipple 6 mm. Hereby,
the most peripheral or most central papillomas are not
feasible for the BLES.
The procedure was performed under ultrasound or ster-
eotactical guidance by experienced senior breast radiolo-
gists. If residual lesion was seen, the procedure could be
repeated. In case of two samples, the nipple’s side of the
specimen was inked so that the pathologist could better
orientate for excision completeness. Clip mark was inserted
into the biopsy site. The 1 cm skin incision was closed with
strips. Total procedure time was approximately 50 min.
BLES samples optimally fixed in 10% buffered formalin
were sliced for processing, sectioning into 3 mm thick sec-
tions and staining with hematoxylin and eosin according to
approved methods and protocols in pathology laboratory.
Samples were examined by pathologists specialized in breast
pathology. In case of suspicion of e.g. ADH or malignancy
adjunctive immunohistochemical stains were performed.
The sections were stained with Ventana Benchmark XT
(Roche, Ventana, Tucson, AZ), using biotin-free, three step
multimer based detection kit Optiview (760-700, Roche,
Ventana, Tucson, AZ). The protocol was based on heat-
induced epitope retrieval using standard pretreatment buffer
CC1, 64 min. The slides were incubated for 40 min with
the primary antibody to CK5/6, ER and SMMHC diluted
1:100. The slides were then dehydrated and mounted for
viewing with microscope.
Histological margin status of the BLES sample was
recorded and categorized into two groups: complete
removal and partial removal (positive margin).Data analysisAll cases were discussed at a multidisciplinary team
(MDT) meeting after final histopathological diagnosis in
order to decide upon definitive management: routine
Fig. 1. The Breast Lesion Excision System (Intact).
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Table 1
Characteristics of the patients, the procedure and the lesions.
N procedures ¼ 80
(N patients ¼ 74)

















15 þ 20 2 3%
12 þ 20 1 1%
Tumor size (mm) median 7 range 3e16





Type of radiological finding
Irregular mass 8 10%
Cystic and solid mass 11 14%
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In cases of further surgery, the surgical resection pathology
was recorded as were the MDT recommendations after
surgery. Follow-up imaging findings were gathered until
June 2016 of those patients who were referred to our unit
for the follow-up. The collected data included the size of
the lesion on imaging, morphology and the BI-RADS clas-
sification of the lesion, the method of prior needle biopsy
and the size of the wire basket used.
The pathological diagnosis of the BLES sample was
compared with the needle biopsy result. We recorded
the number of cases that were upgraded to a HRL such
as ADH or lobular carcinoma in situ (LCIS), DCIS or
to invasive carcinoma by the BLES. Percentage of com-
plete removals was evaluated. We also looked at all the
complications or difficulties related to the procedure. In
addition, we performed a centralized re-evaluation of all
samples with unclear pathology reports. An experienced
breast pathologist re-evaluated these samples and pre-
sented a definitive interpretation.
Results
In total, 74 patients with a histological or cytological and
radiological suspicion of an intraductal papilloma under-
went 80 BLES procedures. The characteristics of the pa-
tients and the lesions are summarized in Table 1.Circumscribed mass 56 70%
Microcalcifications 4 5%Radiological findings
Architectual distorsion 1 1%
a Core needle biopsy.
b Fine needle aspiration cytology.
c In one BI-RADS 4 lesion, neither previous CNB nor FNAC was per-
formed, but the lesion was biopsied with the BLES at the same session
with another papilloma with a previous CNB.56 (70%) of the lesions were circumscribed masses, 11
cystic and solid masses, eight irregular masses, four micro-
calcifications and one architectural distortion (Table 1). 67
(84%) cases were classified as BI-RADS 4 and only two as
BI-RADS 5.Histopathological findingsPathological diagnosis after the BLES biopsy confirmed
an intraductal papilloma without atypia in 43 lesions
(Table 2, Fig. 2). In total, 10 lesions were upgraded to HRL
with either ADH or LCIS: Six lesions were diagnosed as in-
traductal papillomas with areas of ADH. Three cases were
upgraded to ADH without an intraductal papilloma. One pa-
tient was found to have LCIS in addition to the papilloma.
Five cases were upgraded to malignancy, two of them had
invasive ductal carcinomas and three had DCIS grade 2. All
these lesions were BI-RADS 4: three circumscribed masses,
one cystic and solid mass and one microcalcification.
The distribution of the lesion excision margins is pre-
sented in Tables 2 and 3. The median radiological size of
the lesions which were excised completely was 7 mm
(4e12 mm) whereas the mean size of the lesions excised
partially was 9 mm (4e16 mm). In both of the cases of
invasive carcinomas, the margins were tumor-positive.
For one of the DCIS cases, the data of the margin in theBLES sample was missing, but there was no residual
DCIS found on the surgical specimen. We found no differ-
ence in the type of radiological abnormality with respect to
the BLES sample margins.
In total, 18 lesions were diagnosed as other benign
lesions (fibrocystic disease, fibrosis, adenosis or fibroade-
noma). Three of them had a needle-biopsy based suspicion
of an intraductal papilloma and ADH and thereby they were
downgraded by BLES.Complications and challenges with the procedureTwo (2.5%) procedures failed technically. One proced-
ure was unsuccessful due to small size of the breast and
another one failed due to a hematoma which occurred after
the injection of the anesthetic solution causing a loss of the
visibility. These cases were biopsied surgically.
Two other cases were unsuccessful as a diagnostic pro-
cedure. In the other case the BLES indicated only fibro-
cystic disease, but since the patient had clear discharge
Table 2
Histopathological findings and margins.
N procedures ¼ 80 (N patients ¼ 74) Complete excision Partial excision Uncleara
PAPILLOMAS 43 19 (44.2%) 24 (55.8%) thermal damage in 2
High-risk lesions 10 6 (60%) 4 (40%)
ADHb þ PAPILLOMA 6 4 2 thermal damage in 1
ADHb 3 1 2 thermal damage in 2
LCISc þ PAPILLOMA 1 1 e
Malignant 5 2 (40%) 2 (40%) 1 (20%)
DCISd,e 3 2 0 1
CARCINOMA 2 0 2
total 58 27 (46.6%) 30 (51.7%) 1 (1.7%)
a One sample with DCIS had unclear margin and presented as circumscribed mass on imaging.
b Atypical ductal hyperplasia.
c Lobular carcinoma in situ.
d Ductal carcinoma in situ.
e All DCIS lesions were grade 2.
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still showed a suspicion of an intraductal papilloma. The
patient underwent surgery and the surgical specimen
revealed multiple papillomas and ADH. The other one
was diagnosed as fibrocystic disease by BLES but due to
radiological suspicion the patient went through a surgical
excision with a final histological diagnosis of DCIS. This
indicates that in these two cases the BLES basket did not
manage to catch the right target.
In five histological report (6%) there was a remark of
thermal artefacts, none of which disturbed the histopatho-
logical analysis.
There were no complications that would have needed
operative treatment. One hematoma turned into an ab-
scess and was treated with oral antibiotics. Minoracore needle biopsy 
b fine needle aspiration cytology 
cBreast Lesion Excision System 














Fig. 2. Feasibility of the BLES procedure andhematomas were not documented. Only one thermal
injury of the skin occurred, it was excised under local
anesthesia in the outpatient clinic right after the BLES
procedure.Further surgery and follow-upSurgical removal was performed for all invasive carci-
nomas and DCIS in order to ensure negative histological
margins. On surgical excision, no invasive carcinoma was
found on specimen, only DCIS or ADH. Surgical biopsy
was performed also in four of the intraductal papillomas
and in one ADH case, in three of these cases there was















distribution of histopathological findings.
Table 3





Size, median (range) 7 mm (4e12 mm) 9 mm (4e16 mm)
Type of radiological abnormality
Circumscribed massa 20 (74.0%) 20 (66.7%)
Cystic and solid mass 4 (14.8%) 5 (16.7%)
Irregular mass 2 (7.4%) 3 (10.0%)
Microcalcification 1 (3.7%) 1 (3.3%)
Architectual distortion e 1 (3.3%)
a One sample with DCIS had unclear margin and presented as circum-
scribed mass on imaging.
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new intraductal papilloma in another location than the first
one. Those were excised by BLES and they are included in
this study. One patient has been diagnosed with a lobular
carcinoma, it was found on the same side as the previous
intraductal papilloma but in a different location. The rest
of the patients have not had any papilloma recurrences.
DiscussionBLES for benign and HRLThis study reports a series of 80 BLES procedures for
lesions with a suspicion of an intraductal papilloma. In
our series, the BLES procedure was adequate in the man-
agement of 71 lesions (89%) (Fig. 2). Thus, the BLES pro-
cedure rendered surgical excision obsolete in these patients.
BLES can be carried out as a quick outpatient procedure
and it is presumably more cost-effective than image-
guided surgical biopsy requiring marking of non-palpable
lesions beforehand. The cosmetic outcome of BLES pro-
cedure is good with just 1 cm scar. The procedure causes
only moderate pain and no sick leave is needed.
No papilloma recurrences, HRL nor malignant tumors
have been found during the follow-up in patients without
surgical re-excision. The current treatment protocol of
HRL in our unit is that there is no need for clear margins,
it is sufficient to confirm the diagnosis with adequate sam-
pling, i.e. with the BLES in selected cases. These patients
are managed with follow-up. The standard care in patients
with DCIS or invasive carcinoma is surgical excision.
There are several previous studies reporting on the use
of BLES for sampling breast lesions but only few reports
on performing complete excisions or using the BLES in
the management of intraductal papillomas. Whitworth
et al. [13] published a large series of 1170 patients who
underwent a BLES for a mainly diagnostic purpose. They
reported that none of the non-ADH lesions (lobular
neoplasia, papilloma or radial scar) were upgraded to carci-
noma on surgical excision or on radiological follow-up, so
they suggested that there is no need of subsequent surgery.
Seror et al. [11] studied the accuracy of BLES and the pre-
dictive factors for complete excision: 30% of the lesionswere completely removed by BLES, and they were smaller
in size. This is comparable with our findings.
Allen et al. [14] reported BLES to be an efficacious
method in excising lesions smaller than 1 cm. Among the
76 patients, they reported that 13 out of the 15 papillomas
and all four ADH lesions were completely removed by
BLES. In the other study by Allen et al. [10] 41 patients un-
derwent BLES procedure in order to completely excise a
high-risk or malignant lesion. The margins were clear for
three out of the nine HRL and for 15 out of the 23 DCIS.
None of the invasive carcinomas were completely removed.
These results are also similar with ours.
There is a recent study from Scaperrotta et al. [17] using
the BLES for small clusters of suspicious microcalcifica-
tions (BI-RADS 4) in 105 patients. They report that the
BLES allows better histological interpretation and lower
underestimation than VACNB, and they suggest it may
have potential for a therapeutic role in selected patients.
There are also studies of using selective ductectomy for
the management of intraductal papillomas. Selective duc-
tectomy procedure requires that there is discharge coming
from a duct and the duct can be cannulated. It is performed
usually under general anesthesia and an incision of about
one-third of the length of the areolar border is needed.
Thus, selective ductectomy is more invasive procedure
than BLES. However, unlike BLES, the procedure is suit-
able also for lesions that are close to the areola. A study of
using selective ductectomy for the diagnosis and treatment
of intraductal papillary lesions with single duct discharge
by Maraz et al. [18] included 100 patients. They reported
6 cases of malignancy. Nine patients had ADH with papil-
loma and one patient had lobular neoplasia around the pap-
illoma. This is comparable to our study.BLES risks and complicationsThe present study confirms that BLES procedure is well
tolerated as there were no major complications. Only one
notable hematoma occurred, similarly to previous studies
[10e12,14]. There were technical problems or insufficient
sampling in a few cases but we want to highlight that
none of the BLES cases were excluded despite a learning
curve. In our series, one skin burn occurred; Al-Harathee
et al. [19] reported two skin burns in their study which
included 134 procedures. The only hematoma in our series
turned into an infection. Sie et al. [16] reported one infec-
tion too but no other complications.
Thermal artefacts on BLES specimens have been re-
ported in several studies [11,12,15,17,20]. However, it has
been stated that thermal damage did not affect the diag-
nostic outcome. Our study supports these findings.Limitations and future aspectsThere was no standardized treatment protocol for BLES
cases at our unit during the study period. The cases were
65L. Niinikoski et al. / EJSO 44 (2018) 59e66discussed at the MDT and the definite management was
decided individually. The follow-up period is rather short
for some patients for making strong conclusions on
recurrences.
There is a recently published study of using VACNB in
the management of breast lesions [20]. However, the
margin assessment is not feasible in VACNB specimen as
the procedure removes the lesions piece by piece. Addition-
ally, VACNB is not suitable for patients with an increased
risk of bleeding since it does not perform hemostasis. On
the other hand, with VACNB there are less limitations
with respect to the location of the lesion; the BLES basket
requires more space to open up.
That study by Strachan et al. [21] introduced a two-way
protocol, one for lesions with atypia and one for lesions
without atypia. Patients with atypia in CNB but not upgraded
or downgraded by VACNB are offered 5-year mammo-
graphic follow-up. The patients without atypia in both
CNB and in VACNB are discharged to routine screening.
However, there is a significant difference in the manage-
ment of patients with a CNB diagnosis of a breast lesion
without atypia but epithelial atypia found on VACNB;
they were offered diagnostic surgical biopsy since with
VACNB it is not possible to preserve the lesion architecture
and differentiate ADH from DCIS, unlike with BLES. This
is a clear advantage of the BLES method. Nevertheless,
their two-way follow-up protocol seems rational and could
be adopted in our unit with the BLES method.
The BLES procedure also has a potential for manage-
ment of selected small carcinomas. Further clinical trials
are required to assess whether it is possible to achieve
clear margins in excising malignant lesions. The BLES
device with 30 mm wire basket is already in use in the
United States.
Conclusion
Breast imaging with more and more accurate imaging
technology is detecting a growing number of small breast
lesions leading to possible over diagnoses and over treat-
ment since the majority of lesions have a very low risk of
malignancy. The BLES procedure is an acceptable method
for the management of small benign and high-risk breast
lesions such as intraductal papillomas. Thus, a great
amount of diagnostic surgical biopsies could be avoided.
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